Optimal summary of information in longitudinal CA125 measurements for efficient ovarian cancer screening

被引:0
|
作者
Skates, SJ [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
来源
JOURNAL OF CLINICAL LIGAND ASSAY | 2000年 / 23卷 / 02期
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Ovarian cancer mortality rates have changed little over 30 years despite therapeutic advances. Given the large proportion of cases discovered in late stages and consequent poor prognosis, and the excellent prognosis if discovered in early stages, screening is an appealing approach to investigate reducing ovarian cancer mortality, Due to the large scale of screening programs end the low incidence of ovarian cancer, it is paramount that the screening strategy is as efficient as possible. CA125 is a marker for ovarian cancer that shows promise in detecting most ovarian cancers preclinically. However, its efficiency could be substantially improved if longitudinal CA125 values were taken into account in the screening program, We provide a detailed description, with minimal mathematical notation, of a systematic statistical calculation to optimally summarize the information in longitudinal CA125 values. Based on this calculation we describe a strategy, called the risk of ovarian cancer algorithm (ROCA), which implements an efficient approach to screening for ovarian cancer based on longitudinal CA125 measurements.
引用
收藏
页码:150 / 154
页数:5
相关论文
共 50 条
  • [41] Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
    Chen, Zhixiang
    Liang, Qianxin
    Zeng, Hua
    Zhao, Qing
    Guo, Zhaodi
    Zhong, Rihui
    Xie, Manlin
    Cai, Xiuping
    Su, Jing
    He, Zhiliang
    Zheng, Lei
    Zhao, Kewei
    JOURNAL OF CANCER, 2020, 11 (21): : 6445 - 6453
  • [42] INITIAL RESULTS WITH OVARIAN-CANCER ANTIGEN CA125
    CANNEY, PA
    MOORE, M
    JAMES, RD
    WILKINSON, PM
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 261 - 261
  • [43] HE4 AND CA125 IN OVARIAN CANCER PATIENTS
    Kotowicz, B.
    Fuksiewicz, M.
    Kowalska, M.
    Sobiczewski, P.
    Skrzypczak, M.
    Spiewankiewicz, B.
    Kaminska, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [44] CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients - From The Danish "MALOVA" Ovarian Cancer Study
    Hogdall, Estrid V. S.
    Christensen, Lise
    Kjaer, Susanne K.
    Blaakaer, Jan
    Kjaerbye-Thygesen, Anette
    Gayther, Simon
    Jacobs, Ian J.
    Hogdall, Claus K.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 508 - 515
  • [45] A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer
    Salminen, Liina
    Nadeem, Nimrah
    Jain, Shruti
    Grenman, Seija
    Carpen, Olli
    Hietanen, Sakari
    Oksa, Sinikka
    Lamminmaki, Urpo
    Pettersson, Kim
    Gidwani, Kamlesh
    Huhtinen, Kaisa
    Hynninen, Johanna
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 689 - 694
  • [46] Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population
    Blyuss, Oleg
    Burnell, Matthew
    Ryan, Andy
    Gentry-Maharaj, Aleksandra
    Marino, Ines P.
    Kalsi, Jatinderpal
    Manchanda, Ranjit
    Timms, John F.
    Parmar, Mahesh
    Skates, Steven J.
    Jacobs, Ian
    Zaikin, Alexey
    Menon, Usha
    CLINICAL CANCER RESEARCH, 2018, 24 (19) : 4726 - 4733
  • [47] CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    Fleming, Nicole D.
    Cass, Liana
    Walsh, Christine S.
    Karlan, Beth Y.
    Li, Andrew J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 249 - 252
  • [48] CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer
    Memarzadeh, S
    Lee, SB
    Berek, JS
    Farias-Eisner, R
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (02) : 120 - 124
  • [49] SCREENING FOR OVARIAN-CANCER USING SERUM CA125 AND VAGINAL EXAMINATION - REPORT ON 2550 FEMALES
    GROVER, S
    QUINN, MA
    WEIDEMAN, P
    KOH, H
    ROBINSON, HP
    ROME, R
    CAUCHI, M
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1995, 5 (04) : 291 - 295
  • [50] TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer
    Yang, Wei-Lei
    Simmons, Archana
    Lu, Zhen
    Baggerly, Keith
    Lu, Karen
    Gentry-Maharaj, Alex
    Menon, Usha
    Jacobs, Ian
    Bast, Robert C.
    CANCER RESEARCH, 2015, 75